Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.66 SEK | -5.67% | -7.82% | -26.11% |
Apr. 29 | Ziccum AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 14 | Ziccum AB Inhalable mRNA/LNP Project Confirms Excellent Properties Obtained by LaminarPace | CI |
Sales 2022 | 17K 1.59K | Sales 2023 | 6.32M 589K | Capitalization | 106M 9.86M |
---|---|---|---|---|---|
Net income 2022 | -28M -2.61M | Net income 2023 | -21M -1.96M | EV / Sales 2022 | 748 x |
Net cash position 2022 | 21.52M 2.01M | Net cash position 2023 | 2.14M 199K | EV / Sales 2023 | 16.4 x |
P/E ratio 2022 |
-1.19
x | P/E ratio 2023 |
-4.94
x | Employees | 9 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 75.41% |
1 day | -5.67% | ||
1 week | -7.82% | ||
Current month | -6.91% | ||
1 month | -10.73% | ||
3 months | -14.76% | ||
6 months | -12.92% | ||
Current year | -26.11% |
Managers | Title | Age | Since |
---|---|---|---|
Ann Gidner
CEO | Chief Executive Officer | 58 | 22-05-08 |
Johny Humaloja
DFI | Director of Finance/CFO | 58 | 23-06-14 |
Chairman | 44 | 17-04-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 44 | 17-04-04 | |
Per Magnus Gerde
BRD | Director/Board Member | - | - |
Director/Board Member | 44 | 21-04-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 5.66 | -5.67% | 43,836 |
24-05-21 | 6 | +2.04% | 21,246 |
24-05-20 | 5.88 | -1.01% | 21,007 |
24-05-17 | 5.94 | +0.34% | 6,924 |
24-05-16 | 5.92 | -3.58% | 8,088 |
Delayed Quote Nasdaq Stockholm, May 22, 2024 at 11:24 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-26.11% | 8.62M | |
-1.59% | 89.49B | |
+2.24% | 40.67B | |
-12.97% | 33.15B | |
+61.72% | 26.45B | |
-20.71% | 14.69B | |
-7.31% | 12.89B | |
-12.64% | 11.54B | |
-42.60% | 11.34B | |
+4.27% | 8.84B |
- Stock Market
- Equities
- ZICC Stock